PolyPid Ltd. is a pharmaceutical company. It discovers, develops and commercializes antibiotic drugs for the prevention of surgical infections. The company's product candidate includes D-PLEX100, BONYPID-1000 and BONYPID-500 which are in clinical stage. PolyPid Ltd. is based in Petach Tikva, Israel.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-29.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -1069.37% |
| Return on Assets (Trailing 12 Months) | -151.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 4.43 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.01 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.70 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.91 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.30 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 10.19M |
| Free Float | 7.67M |
| Market Capitalization | $28.43M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 1.25 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 24.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 26.47% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |